{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:03:38Z","timestamp":1792807418233,"version":"4.5.0"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI121627"],"award-info":[{"award-number":["R21 AI121627"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI121627"],"award-info":[{"award-number":["R21 AI121627"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Bacteriophage therapy is a promising alternative treatment to antibiotics, as it has been documented to be efficacious against multidrug-resistant bacteria with minimal side effects. Several groups have demonstrated the efficacy of phage suspension\n            <jats:italic>in vivo<\/jats:italic>\n            to treat lung infections using intranasal delivery; however, phage dry-powder administration to the lungs has not yet been explored. Powder formulations provide potential advantages over a liquid formulation, including easy storage, transport, and administration. The purpose of this study was to assess the bactericidal activities of phage dry-powder formulations against multidrug-resistant (MDR) strain\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            FADDI-PA001 in a mouse lung infection model. Phage PEV20 spray dried with lactose and leucine produced an inhalable powder at a concentration of 2 \u00d7 10\n            <jats:sup>7<\/jats:sup>\n            PFU\/mg.\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            lung infection was established by intratracheal administration of the bacterial suspension to neutropenic mice. At 2 h after the bacterial challenge, the infected mice were treated with 2 mg of the phage powder using a dry-powder insufflator. At 24 h after the phage treatment, the bacterial load in the lungs was decreased by 5.3 log\n            <jats:sub>10<\/jats:sub>\n            (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.0005) in the phage-treated group compared with that in the nontreated group. Additionally, the phage concentration in the lungs was increased by 1 log\n            <jats:sub>10<\/jats:sub>\n            at 24 h in the treated group. These results demonstrate the feasibility of a pulmonary delivery of phage PEV20 dry-powder formulation for the treatment of lung infection caused by antibiotic-resistant\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            .\n          <\/jats:p>","DOI":"10.1128\/aac.01714-17","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T17:10:26Z","timestamp":1511197826000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":80,"title":["Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation"],"prefix":"10.1128","volume":"62","author":[{"given":"Rachel Yoon Kyung","family":"Chang","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[{"name":"Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia"},{"name":"Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiping","family":"Wang","sequence":"additional","affiliation":[{"name":"Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia"},{"name":"Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wallin","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Sydney, Sydney, Australia"},{"name":"Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warwick","family":"Britton","sequence":"additional","affiliation":[{"name":"Tuberculosis Research Program, Centenary Institute and Sydney Medical School, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Morales","sequence":"additional","affiliation":[{"name":"AmpliPhi Biosciences AU, Brookvale, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Kutter","sequence":"additional","affiliation":[{"name":"The Evergreen State College, Olympia, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak-Kim","family":"Chan","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.4187\/aarc0537"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.11.90"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.4161\/viru.25991"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.4161\/bact.1.2.14590"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/651135"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016963"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00029-12"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv267"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02025-16"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00211-17"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22715"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-016-1892-6"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2012.12.022"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068797"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.01.060"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2017.09.002"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2016.02.010"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(97)00113-0"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/649227"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2015.1233"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.4103\/0970-2113.92361"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2005.04.009"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/fpd.2008.0242"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12275-011-1512-4"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01714-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01714-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:09:32Z","timestamp":1645477772000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01714-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1128\/AAC.01714-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01714-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"2017-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01714-17"}}